DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
QUEST DIAGNOSTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026
$234.91−0.09 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $26.31B
- P/E (TTM)
- 25.0
- Dividend yield
- –
QUEST DIAGNOSTICS INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIS business | $10.79B | $9.61B | $8.98B | $9.61B | $10.49B | $9.14B | $7.41B | $7.20B | $7.07B | $6.84B | 97.7% | +12.2% |
| All other operating segments | $250.00M | $258.00M | $276.00M | $274.00M | $294.00M | $298.00M | $321.00M | $327.00M | $334.00M | $377.00M | 2.3% | -3.1% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DIS business | $1.83B | $1.63B | $1.55B | $1.70B | $2.65B | $2.20B | $1.30B | $1.24B | $1.31B | $1.24B | +12.2% |
| All other operating segments | $32.00M | $33.00M | $34.00M | $20.00M | $29.00M | $39.00M | $42.00M | $47.00M | $52.00M | $64.00M | -3.0% |
| General corporate activities | -$305.00M | -$317.00M | -$319.00M | -$296.00M | -$294.00M | -$269.00M | -$109.00M | -$181.00M | -$200.00M | -$31.00M | -3.8% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All other services | – | – | – | – | $294.00M | $298.00M | $321.00M | $327.00M | $335.00M | $377.00M | – | – |
| Anatomic pathology testing services | – | – | – | – | $553.00M | $482.00M | $579.00M | $578.00M | $612.00M | $624.00M | – | – |
| Gene-based and esoteric (including advanced diagnostics) testing services | – | – | – | – | $2.88B | $2.10B | $2.62B | $2.41B | $2.45B | $2.34B | – | – |
| Routine clinical testing and other services | – | – | – | – | $4.29B | $3.84B | $4.21B | $4.22B | $4.01B | $3.88B | – | – |
| COVID-19 testing services | – | – | – | – | $2.77B | $2.72B | $0 | $0 | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Quest Diagnostics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.